Expert Opinion on Therapeutic Targets,
Journal Year:
2021,
Volume and Issue:
25(8), P. 645 - 658
Published: Aug. 3, 2021
:
Hepatocellular
carcinoma
(HCC)
is
a
malignant
liver
tumor
characterized
by
high
molecular
heterogeneity,
which
has
hampered
the
development
of
effective
targeted
therapies
severely.
Recent
experimental
data
have
unraveled
novel
promising
targets
for
HCC
treatment.:
Eligible
articles
were
retrieved
from
PubMed
and
Web
Science
databases
up
to
July
2021.
This
review
summarizes
established
advanced
HCC,
focusing
on
strategies
overcome
drug
resistance
search
combinational
treatments.
In
addition,
conventional
biomarkers
holding
promises
treatments
therapeutic
research
field
are
discussed.:
molecularly
complex
disease,
with
several
distinct
pathways
playing
critical
roles
in
different
subtypes.
Experimental
models
recapitulating
features
each
subset
would
be
highly
beneficial
design
more
against
this
disease.
Furthermore,
deeper
understanding
combinatorial
synergism
role
microenvironment
will
lead
improved
outcomes.
Journal of Cannabis Research,
Journal Year:
2023,
Volume and Issue:
5(1)
Published: July 12, 2023
Targeting
protein
kinase
B
(Akt)
and
its
downstream
signaling
proteins
are
promising
options
in
designing
novel
potent
drug
candidates
against
hepatocellular
carcinoma
(HCC).
The
present
study
explores
the
anti-HCC
potentials
of
Cannabis
sativa
(C.
sativa)
extract
via
involvement
Akt
using
both
silico
vivo
animal
models
HCC
approaches.
Hepatology Communications,
Journal Year:
2022,
Volume and Issue:
6(12), P. 3550 - 3562
Published: Oct. 4, 2022
Liver
cancer,
comprised
primarily
of
hepatocellular
carcinoma
(HCC),
is
the
third
leading
cause
cancer
deaths
worldwide
and
increasing
in
Western
countries.
We
previously
identified
transcription
factor
zinc
fingers
homeoboxes
2
(Zhx2)
as
a
regulator
hepatic
gene
expression,
many
Zhx2
target
genes
are
dysregulated
HCC.
Here,
we
investigate
HCC
Zhx2-deficient
mice
using
diethylnitrosamine
(DEN)-induced
liver
tumor
model.
Our
study
whole-body
knockout
(Zhx2KO
)
revealed
complete
absence
tumors
9
10
months
after
DEN
exposure.
Analysis
soon
treatment
showed
no
differences
expression
bioactivating
enzyme
cytochrome
P450
2E1
(CYP2E1)
DNA
polymerase
delta
2,
or
numbers
phosphorylated
histone
variant
H2AX
foci
between
Zhx2KO
wild-type
(Zhx2wt
mice.
The
Zhx2,
therefore,
did
not
alter
bioactivation
damage.
livers
fewer
positive
for
Ki67
staining
reduced
interleukin-6
AKT
serine/threonine
kinase
compared
with
Zhx2wt
livers,
suggesting
that
loss
reduces
cell
proliferation
may
account
formation.
Tumors
were
but
absent
DEN-treated
liver-specific
mice,
acts
both
hepatocytes
nonparenchymal
cells
to
inhibit
data
from
Cancer
Genome
Atlas
Clinical
Proteomic
Tumor
Consortium
indicated
ZHX2
messenger
RNA
protein
levels
significantly
higher
patients
associated
clinical
pathological
parameters.
Conclusion:
In
contrast
previous
studies
human
hepatoma
lines
other
mouse
models
showing
suppressor,
our
indicate
an
oncogene
DEN-induced
model
consistent
